Denmark's Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera , after Pfizer in ...

Founded in 2022 by Population Health Partners and ARCH Venture Partners, the biotech venture giant led by Bob Nelsen, Metsera ...

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...

By Maggie Fick LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an ...

Explore the fierce competition between Novo Nordisk and Pfizer as they vie for Metsera amidst a booming obesity drug market.

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited ...

I don’t know what to say about Pfizer. I mean, it’s got that yield of 7%. It bought that Seagen. I thought it was going to ...

Novo's offer, which comes with $56.50 per share upfront along with another $2.5 billion tied to future milestones, ...

Denmark's Novo Nordisk launched a rival bid for U. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

Novo Nordisk's surprise bid for Metsera has set the stage for a high-stakes showdown in the obesity drug market, with Pfizer ...